SAN JOSE, Calif., Dec. 2, 2019 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on harnessing the body's immune system in the fight against cancer,
today announced that data from its ongoing studies utilizing
Cchek™, its artificial intelligence (AI) driven early cancer
detection technology will be presented during a poster session at
the San Antonio Breast Cancer Symposium (SABCS).
The symposium takes place December
10 – 14, 2019 in San Antonio,
TX, and is designed to provide state-of-the-art information
on the experimental biology, etiology, prevention, diagnosis, and
therapy of breast cancer and premalignant breast disease. The
meeting will be attended by both U.S. and international researchers
and healthcare professionals who are involved in breast cancer
research and clinical care.
Poster presentation details are as follows:
Title: Combining HyperVOX with pattern
recognition neural networks: A new method for analyzing flow
cytometry-based immunophenotyping data for increased early
detection of stage I/II breast cancer (BCa)
Authors: George A. Dominguez, Ph.D.; John
Roop; Alex Polo; Anthony J. Campisi; Dmitry I. Gabrilovich, MD, Ph.D.; Amit Kumar, Ph.D.
Poster Session and Number: Session 5,
Location: Henry B. Gonzalez Convention Center,
Date and Time: Friday, December 13, 2019
(5:00 PM – 7:00 PM CT)
To receive a copy of the presentation, please email your request
to SABCSfirstname.lastname@example.org starting December
14, 2019 and include your name, title, and contact
Cchek™ is an early cancer detection
technology, that measures a patient's immunological response to a
malignancy by analyzing immune system cells in peripheral blood.
The goal is to utilize the technology to determine a
patient's cancer status from a simple blood draw, eliminating the
need for a biopsy, which can be an expensive, painful and invasive
procedure. Further, conventional methods using current cancer
screening tests often lack accuracy and reliability. Anixa's
orthogonal approach using flow cytometry coupled with artificial
intelligence provides an alternative method that offers improved
affordability, efficacy and efficiency. To date, Anixa has
successfully used Cchek™ to detect the presence of 20 different
cancers including lung, colon, breast and prostate. The
robust cancer detection performance of Cchek™ makes it a platform
from which multiple cancer diagnostic tests may be developed.
The first such test, a prostate cancer confirmation test, is slated
for commercial launch by the end of 2019.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company focused on harnessing the
body's immune system in the fight against cancer. Anixa's
therapeutic portfolio includes a cancer vaccine technology focused
on the immunization against α-Lactalbumin to prevent triple
negative breast cancer (TNBC), as well as a cancer immunotherapy
program which uses a novel type of CAR-T, known as chimeric
endocrine receptor T-cell (CER-T) technology. The company's
diagnostic portfolio consists of Cchek™, a liquid biopsy technology
for early detection of solid tumors based on the body's immune
response to the presence of a malignancy. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements
that are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
Johanna Bennett (Media)
View original content to download
SOURCE Anixa Biosciences, Inc.